Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that Tucker Kelly, CFO, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 4:20 PM ET in Miami. A live webcast will be available on Deciphera’s Investors page, with a replay archived for 90 days. Deciphera is focused on developing innovative medicines for cancer treatment, utilizing its unique switch-control kinase inhibitor platform. Their product, QINLOCK®, is approved in several markets, including the U.S. and Europe, for treating fourth-line GIST.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005137/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Tucker Kelly participate in the Barclays Global Healthcare Conference?

Tucker Kelly will participate in the Barclays Global Healthcare Conference on March 16, 2022, at 4:20 PM ET.

Where can I watch the Deciphera Pharmaceuticals event webcast?

The live webcast can be viewed on the 'Events and Presentations' page in the Investors section of Deciphera's website.

What is QINLOCK® and where is it approved?

QINLOCK® is Deciphera's switch control inhibitor for fourth-line GIST, approved in multiple regions including the U.S., EU, Canada, and Australia.

How long will the webcast replay be available?

The replay of the webcast will be archived on Deciphera’s website for 90 days following the presentation.